Skip to Content Facebook Feature Image

Amcor appoints Peter Konieczny as Chief Executive Officer

Business

Amcor appoints Peter Konieczny as Chief Executive Officer
Business

Business

Amcor appoints Peter Konieczny as Chief Executive Officer

2024-09-05 04:10 Last Updated At:04:25

ZURICH, Sept. 5, 2024 /PRNewswire/ -- Amcor (NYSE: AMCR; ASX: AMC), a global leader in developing and producing responsible packaging solutions, today announced that its Board of Directors has appointed Peter Konieczny as Chief Executive Officer (CEO). Mr. Konieczny has served as Interim CEO since April 2024. The Board also intends to nominate him as a director for election at the Company's Annual Meeting of Shareholders which is expected to be held in November 2024.

Amcor Chairman, Mr. Graeme Liebelt, said, "Peter has demonstrated exceptional leadership in every role he has held during his career at Amcor, including as Interim CEO where he has led the Company through a period of strengthening financial performance and set the business up for further progress. The Board and I are confident Peter is the right person to lead Amcor, and we look forward to working with him to build on the strong foundation the Company has established over many years."

Mr. Konieczny said, "I am honored and grateful for the opportunity to lead Amcor as Chief Executive Officer. Amcor is an outstanding company with highly talented people, a strong sense of purpose, a proven culture of execution and most importantly, significant growth potential."

"The business finished fiscal 2024 well with strong earnings growth, giving us confidence that momentum in the underlying business will continue to build in fiscal 2025 and beyond. Together with our continued commitment to safety, customer success and disciplined capital allocation, I believe Amcor is very well positioned to deliver industry leading value for our customers, our shareholders and the environment."

About Peter Konieczny

Mr. Konieczny has been a member of the Amcor Global Management Team since 2010 and was appointed Interim Chief Executive Officer in April 2024. Between September 2020 and April 2024, Mr. Konieczny served as Chief Commercial Officer (CCO), where he oversaw global category and product management, Sustainability, R&D and Procurement while maintaining responsibility for the Amcor Flexibles Latin America business. He also served as President, Amcor Flexibles, Europe, Middle East & Africa and Latin America between 2019 and 2020, President, Amcor Flexibles Europe, Middle East & Africa between 2015 and 2019, and President, Amcor Specialty Cartons between 2010 and 2015. Prior to Amcor, he had five years of experience in the packaging industry as President of Silgan White Cap, a global organization specializing in metal and plastic closures for the food and beverage industries. He held business group Managing Director and Chief Finance Officer positions in the heavy industrial equipment industry and has been a management consultant with McKinsey & Company.

About Amcor

Amcor is a global leader in developing and producing responsible packaging solutions across a variety of materials for food, beverage, pharmaceutical, medical, home and personal-care, and other products.  Amcor works with leading companies around the world to protect products, differentiate brands, and improve supply chains. The Company offers a range of innovative, differentiating flexible and rigid packaging, specialty cartons, closures and services. The company is focused on making packaging that is increasingly recyclable, reusable, lighter weight and made using an increasing amount of recycled content. In fiscal year 2024, 41,000 Amcor people generated $13.6 billion in annual sales from operations that span 212 locations in 40 countries.  NYSE: AMCR; ASX: AMC

www.amcor.com I LinkedInYouTube

Cautionary Statement Regarding Forward-Looking Statements

This document contains certain statements that are "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are generally identified with words like "believe," "expect," "target," "project," "may," "could," "would," "approximately," "possible," "will," "should," "intend," "plan," "anticipate," "commit," "estimate," "potential," "ambitions," "outlook," or "continue," the negative of these words, other terms of similar meaning, or the use of future dates. Such statements are based on the current expectations of the management of Amcor and are qualified by the inherent risks and uncertainties surrounding future expectations generally. Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties. Neither Amcor nor any of its respective directors, executive officers, or advisors provide any representation, assurance, or guarantee that the occurrence of the events expressed or implied in any forward-looking statements will actually occur. Risks and uncertainties that could cause actual results to differ from expectations include, but are not limited to: changes in consumer demand patterns and customer requirements in numerous industries; the loss of key customers, a reduction in their production requirements or consolidation among key customers; significant competition in the industries and regions in which we operate; an inability to expand our current business effectively through either organic growth, including product innovation, investments or acquisitions; challenging global economic conditions, impacts of operating internationally; price fluctuations or shortages in the availability of raw materials, energy, and other inputs which could adversely affect our business; production, supply, and commercial risks, including counterparty credit risks, which may be exacerbated in times of economic volatility; pandemics, epidemics, or other disease outbreaks; an inability to attract, motivate and retain our skilled workforce and manage key transitions; labor disputes and an inability to renew collective bargaining agreements at acceptable terms; physical impact of climate change; cybersecurity risks, which could disrupt our operations or risk of loss of our sensitive business information; failures or disruptions in our information technology systems which could disrupt our operations, compromise customer, employee, supplier and other data; a significant increase in our indebtedness or a downgrade in our credit rating could reduce our operating flexibility and increase our borrowing costs and negatively affect our financial condition and results of operations; rising interest rates that increase our borrowing costs on our variable rate indebtedness and could have other negative impacts; foreign exchange rate risk; a significant write-down of goodwill and/or intangible assets; a failure to maintain an effective system of internal control over financial reporting; inability of our insurance policies, including our use of a captive insurance company, to provide adequate protection against all of the risks we face; an inability to defend our intellectual property rights or intellectual property infringement claims against us; litigation, including product liability claims or litigation related to Environmental, Social, and Governance ("ESG") matters or regulatory developments; increasing scrutiny and changing expectations from investors, customers, suppliers and governments with respect to our ESG practices and commitments resulting in additional costs or exposure to additional risks; changing ESG disclosure regulations including climate-related rules; changing environmental, health, and safety laws; changes in tax laws or changes in our geographic mix of earnings; and other risks and uncertainties identified from time to time in Amcor's filings with the U.S. Securities and Exchange Commission (the "SEC"), including without limitation, those described under Item 1A. "Risk Factors" of Amcor's annual report on Form 10-K for the fiscal year ended June 30, 2023 and any subsequent quarterly reports on Form 10-Q. You can obtain copies of Amcor's filings with the SEC for free at the SEC's website (www.sec.gov). Forward-looking statements included herein are made only as of the date hereof and Amcor assumes no obligation, and disclaims any obligation to update any forward-looking statements, or any other information in this communication, as a result of new information, future developments or otherwise, or to correct any inaccuracies or omissions in them which become apparent, except as expressly required by law. All forward-looking statements in this communication are qualified in their entirety by this cautionary statement.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Amcor appoints Peter Konieczny as Chief Executive Officer

Amcor appoints Peter Konieczny as Chief Executive Officer

SHANGHAI, Sept. 20, 2026 /PRNewswire/ -- A news report from Yicai Global:

On September 17, the BioShanghai Week 2026 opened at Zhangjiang Science Hall in Shanghai. Themed "AI for Biopharma, Health for All," this year's event brings together innovation resources from around the world to foster an open, collaborative innovation ecosystem for the biopharmaceutical industry.

The opening ceremony marked the launch of the "Connect Globally: Shanghai–London Life Sciences Innovation Partnership." The ceremony was attended by representatives of Chinese and British institutions, including Zhangjiang Group, Shanghai Minhang Biomedical Industry Development Co., Ltd., Shanghai Jiading Industrial Zone Development (Group) Co., Ltd., London & Partners, Imperial College London, and Oxford University Innovation. Going forward, London Life Sciences Week and BioShanghai Week will work more closely to connect research capabilities, industry resources, and innovation platforms in life sciences across China and the UK, creating an open, efficient platform for international exchange and cooperation.

The ceremony also unveiled the "Empower the Future: BioShanghai Investment and Financing Ecosystem Partnership," bringing together representatives from domestic and foreign equity investment and financial institutions. These included Shanghai Industrial Investment (Holdings) Co., Ltd., Shanghai State-owned Capital Investment Co., Ltd., Advantech Capital, CBC Group, Pudong Venture Capital Group, GL Ventures, HongShan, Jefferies Financial Group, Guotai Haitong Securities, New Alliance Capital, YUNION Healthcare Ventures, and Shanghai Hongsheng Capital. Together, these partners will work to align capital with industry and build a biopharmaceutical capital ecosystem that supports companies at every stage of their life cycle.

The BioShanghai Week 2026 officially opened. Running from September 17 to 20, this event follows a "1+5+1+1" framework: one opening ceremony, five thematic tracks, one exhibition with matchmaking sessions, and one Bio-Tour of industry sites. It brings together entrepreneurs, investors, scientists, clinical PIs, and other key players to address practical challenges in frontier technologies, research commercialization, industry collaboration, and business growth. Activities are organized around five themes: Innovation Integration, Clinical Translation, Capital Empowerment, Ecosystem Services, and Coordinated Healthcare Development. To connect resources efficiently, formats such as "One Room One Topic," closed-door discussion, project roadshows, one-on-one meetings, and Bio-Tour are adopted.

This year, BioShanghai Week returns with an upgraded format, aiming to position itself as a global bellwether for cutting-edge biopharmaceutical technologies and a gateway for cross-border collaboration. Over the years, Zhangjiang Pharma Valley has become an internationally recognized and influential signature brand of the biopharmaceutical industry. Pairing BioShanghai Week with the Zhangjiang brand will further raise both the profile and market vitality of Zhangjiang Pharma Valley, creating a premier annual dealmaking summit that connects global capital with Chinese pharmaceutical innovation and takes Chinese breakthroughs to global markets. These efforts will support Shanghai's ambition to become "the world's most supportive city for innovative drugs and medical devices."

The 2026 Jiading District Biopharmaceutical Industry Development Promotion Conference and the 2026 Minhang District Biopharmaceutical Ecosystem Promotion Conference were held on the same day. Both events support Shanghai's drive to develop high-end medical device industry clusters and help land innovation resources and outcomes in the city.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

BioShanghai Week 2026 Opens -- Joining Forces to Build a Global Biopharmaceutical Innovation Ecosystem

BioShanghai Week 2026 Opens -- Joining Forces to Build a Global Biopharmaceutical Innovation Ecosystem

Recommended Articles